1. Home
  2. GNS vs VERU Comparison

GNS vs VERU Comparison

Compare GNS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genius Group Limited

GNS

Genius Group Limited

HOLD

Current Price

$0.46

Market Cap

48.0M

Sector

Real Estate

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.42

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNS
VERU
Founded
2002
1971
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.0M
40.9M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
GNS
VERU
Price
$0.46
$2.42
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
906.2K
48.9K
Earning Date
03-09-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
$156.26
N/A
Revenue Next Year
$35.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.36
52 Week High
$1.92
$4.59

Technical Indicators

Market Signals
Indicator
GNS
VERU
Relative Strength Index (RSI) 60.10 51.85
Support Level $0.36 $2.13
Resistance Level $0.48 $2.70
Average True Range (ATR) 0.04 0.13
MACD 0.01 0.02
Stochastic Oscillator 88.53 62.94

Price Performance

Historical Comparison
GNS
VERU

About GNS Genius Group Limited

Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: